A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer (opens ClinicalTrials.gov)
- Sponsor
- Incyte Corporation
- Enrolment
- 700
- Started
- 2026-03-05
- Last update
- 2026-10-30
Conditions: CRC (Colorectal Cancer)
Interventions: INCA33890, Placebo, Bevacizumab, FOLFOX